Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388(2) in Healthy Subjects

NCT ID: NCT05189288

Last Updated: 2022-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-01-14
• Study Completion Date: 2022-04-15

Brief Summary

This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects

Detailed Description

To healthy 60 subjects, following treatments are administered dosing in each period and wash-out period is a minimum of 14 days.

Reference drug: D418 Tab. / Test drug: CKD-388 Tab. Pharmacokinetic blood samples are collected up to 72hrs. The pharmacokinetic characteristics and safety are assessed.

Conditions

Chronic Hepatitis b

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Reference-Test

D418 Tab. - CKD-388 Tab.

Group Type: EXPERIMENTAL

D418 Tab.

Intervention Type: DRUG

1T

CKD-388 Tab.

Intervention Type: DRUG

1T

Test-Reference

CKD-388 Tab. - D418 Tab.

Group Type: EXPERIMENTAL

D418 Tab.

Intervention Type: DRUG

1T

CKD-388 Tab.

Intervention Type: DRUG

1T

Interventions

D418 Tab.

1T

Intervention Type: DRUG

CKD-388 Tab.

1T

Intervention Type: DRUG

Other Intervention Names

Reference; Test

Eligibility Criteria

Inclusion Criteria

1. Healthy male volunteers, aged ≥ 19 years old at the time of screening.

2. Weight ≥50kg (man) or 45kg (woman), with calculated body mass index (BMI) of 18 to 30 kg/m2 at the time of screening.

• BMI = Weight(kg)/ Height(m)2

3. Those who have no congenital diseases or chronic diseases and have no abnormal symptoms or findings.

4. Those who are eligible for clinical trials based on laboratory(hematology, blood chemistry, serology, urology) and 12-lead ECG results at screening.

5. Those who agree to contraception during the participation of clinical trial.

6. Individuals who voluntarily decide to participate and agree to comply with the cautions after fully understand the detailed description of this clinical trial.

Exclusion Criteria

1. Those with clinically significant diseases or history in digestive systems, cardiovascular system, endocrine system, respiratory system, blood/tumor, infectious disease, kidney and urogenesis system, mental/nervous system, musculoskeletal system, immune system, otolaryngology, skin system, ophthalmology system, etc.

2. Those who have a history of gastrointestinal surgery except simple appendectomy and hernia surgery.

3. Those who have used drugs that induce or inhibit drug metabolizing enzymes, such as barbiturates, within 1 month before the first dosing date, or who have used drugs that may interfere with this study within 10 days before the first dosing day (However, clinical investigational drugs) Participation is possible in consideration of pharmacokinetic and pharmacodynamic characteristics such as interaction with concomitant drugs and half-life of concomitant drugs)

4. Those who have participated in other clinical trials or bioequivalence studies within 6 months of the first administration date and administered the investigational drug

5. Those who donated whole blood within 8 weeks of the first dose, or donated component blood within 2 weeks, or received blood transfusion within 4 weeks

6. Those who meet the following conditions within 1 month of the first administration date

• In the case of men, alcohol consumption in excess of 21 drinks/week on average
• For women, alcohol consumption in excess of 14 drinks/week on average

(1 glass = 50 mL of soju or 30 mL of Western liquor or 250 mL of beer)

• Smoking in excess of 20 cigarettes per day on average

7. A person who falls under any of the following

• Patients with hypersensitivity to this drug or any of its components
• Because this drug contains lactose, patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption

9. In the case of female volunteers, those who are pregnant or suspected of being pregnant or are lactating

• Minimum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jaewoo Kim

Role: PRINCIPAL_INVESTIGATOR

South Korea

Locations

H plus Yangji hospital

Seoul, , South Korea

Countries

South Korea

Other Identifiers

A99_03BE2122

Identifier Type: -

Identifier Source: org_study_id